[go: up one dir, main page]

PE20001483A1 - Acidos oxamicos y derivados como ligandos de receptores tiroideos - Google Patents

Acidos oxamicos y derivados como ligandos de receptores tiroideos

Info

Publication number
PE20001483A1
PE20001483A1 PE2000000166A PE0001662000A PE20001483A1 PE 20001483 A1 PE20001483 A1 PE 20001483A1 PE 2000000166 A PE2000000166 A PE 2000000166A PE 0001662000 A PE0001662000 A PE 0001662000A PE 20001483 A1 PE20001483 A1 PE 20001483A1
Authority
PE
Peru
Prior art keywords
alkyl
oxamic
heterocycle
phenyl
together form
Prior art date
Application number
PE2000000166A
Other languages
English (en)
Inventor
Robert Lee Dow
Yuan-Ching Phoebe Chiang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20001483A1 publication Critical patent/PE20001483A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A ACIDOS OXAMICOS DE FORMULA I DONDE R1, R2, R3 SON H, HALOGENO, ALQUILO C1-C6, TRIFLUOROMETILO, CN, OCF3, O-ALQUILO C1-C6; R4 ES H, ALQUILO C1-C12, ENTRE OTROS; CUANDO R5 NO ES F; R4 ES SO2NR9R10, CONR9R10, ENTRE OTROS; O R3 Y R4 FORMAN JUNTOS UN CARBOCICLO A: -(CH2)b-, HETEROCICLO A: Q-(CH2)c; (CH2)j-Q-(CH2)k; Q ES O, S, NR17; R5 ES F, OH, ALCOXI C1-C4, OCOR9; R4 Y R5 JUNTOS FORMAN UN HETEROCICLO B: R9C=CR10NH, N=CR9-NH, R9C=CH-O, ENTRE OTROS; R6 ES H, HALOGENO, ALQUILO C1-C4, TRIFLUOROMETILO; R7 ES H, ALQUILO C1-C6; R8 ES OR9, NR19R20; R9 Y R10 SON H, ALQUILO C1-C12, ALQUENILO C2-C12, CICLOALQUILO C3-C10, ARILO, HET, ENTRE OTROS O R9 Y R10 JUNTOS FORMAN UN HETEROCICLO C, ENTRE OTROS, R11 ES ALQUILO C1-C12; R17 ES H, ALQUILO C1-C6, COR9; W ES O, SOd, CH2, NR9; b ES 3-7; c, j Y k SON 2-6. SON COMPUESTOS PREFERIDOS ACIDO N-[3-CLORO-4-(3-CICLOPROPILSULFAMOIL-4-HIDROXI-FENOXI)-5-METIL-FENIL]OXAMICO, ACIDO-N-[4-(3-CICLOPROPILSULFAMOIL-4-HIDROXI-FENOXI)-3,5-DIMETIL-FENIL]OXAMICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS A UN AGENTE ANOREXIGENICO O UN INHIBIDOR DE LIPASA. EL COMPUESTO I ES UN LIGANDO DEL RECEPTOR TIROIDEO Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA OBESIDAD, HIPERLIPIDEMIA, GLAUCOMA, ARRITMIA CARDIACA, TRASTORNOS DE LA PIEL, ENFERMEDAD DE TIROIDES, HIPOTIROIDISMO
PE2000000166A 1999-03-01 2000-02-29 Acidos oxamicos y derivados como ligandos de receptores tiroideos PE20001483A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12229299P 1999-03-01 1999-03-01

Publications (1)

Publication Number Publication Date
PE20001483A1 true PE20001483A1 (es) 2000-12-29

Family

ID=22401838

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000166A PE20001483A1 (es) 1999-03-01 2000-02-29 Acidos oxamicos y derivados como ligandos de receptores tiroideos

Country Status (43)

Country Link
US (3) US6326398B1 (es)
EP (1) EP1157001B1 (es)
JP (2) JP3699355B2 (es)
KR (1) KR20010103786A (es)
CN (2) CN1345303A (es)
AP (1) AP2001002259A0 (es)
AR (1) AR033791A1 (es)
AT (1) ATE272609T1 (es)
AU (1) AU772282B2 (es)
BG (1) BG105954A (es)
BR (1) BR0008701A (es)
CA (1) CA2363145C (es)
CO (1) CO5150228A1 (es)
CR (1) CR6451A (es)
CZ (1) CZ20013117A3 (es)
DE (1) DE60012700T2 (es)
DZ (1) DZ3020A1 (es)
EA (1) EA004229B1 (es)
EE (1) EE200100464A (es)
ES (1) ES2223454T3 (es)
GT (2) GT200000025AA (es)
HK (1) HK1044532A1 (es)
HN (1) HN2000000029A (es)
HR (1) HRP20010633A2 (es)
HU (1) HUP0200248A3 (es)
ID (1) ID29889A (es)
IL (1) IL144765A0 (es)
IS (1) IS6054A (es)
MA (1) MA26723A1 (es)
NO (1) NO20014217L (es)
NZ (1) NZ513449A (es)
OA (1) OA11839A (es)
PA (1) PA8491501A1 (es)
PE (1) PE20001483A1 (es)
PL (1) PL364802A1 (es)
PT (1) PT1157001E (es)
SK (1) SK12102001A3 (es)
TN (1) TNSN00036A1 (es)
TR (1) TR200102561T2 (es)
UY (1) UY26043A1 (es)
WO (1) WO2000051971A1 (es)
YU (1) YU63301A (es)
ZA (1) ZA200106730B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
OA11839A (en) * 1999-03-01 2005-08-23 Pfizer Prod Inc Oxamic acids and derivatives as thyroid receptor ligands.
NZ513825A (en) 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
CZ20022771A3 (cs) 2000-02-17 2003-09-17 Bristol-Myers Squibb Company Ligandy thyreoidního receptoru odvozené od anilinu
AU2001262113A1 (en) * 2000-03-23 2001-10-03 Bayer Aktiengesellschaft Indoles for treating diseases that can be treated using thyroid hormones
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US6395784B1 (en) 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
GB0015205D0 (en) * 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
DE10038007A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
WO2002032408A2 (en) * 2000-10-20 2002-04-25 Novartis Ag Combinations of a thyromimetic compound and a statin
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
DE10110750A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
DE10122443A1 (de) * 2001-05-09 2002-11-14 Bayer Ag Amido-Diphenyl-Derivate
ES2267945T3 (es) * 2001-05-31 2007-03-16 Pfizer Products Inc. Uso medico de compuestos tiromimeticos para tratar la perdida del cabello y composiciones.
CA2455336A1 (en) * 2001-08-10 2003-02-20 Novartis Ag Peptides that bind to atherosclerotic lesions
DE10142668A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
ES2253495T3 (es) 2001-09-26 2006-06-01 Pfizer Products Inc. Acidos indol carboxilicos como ligandos de receptores tiroideos.
EP1448512A1 (en) * 2001-11-17 2004-08-25 NeuroSearch A/S Prodrugs of antidepressants and their use for treating depressions
US7230031B2 (en) 2002-01-30 2007-06-12 Kissei Pharmaceutical Co., Ltd. Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
EP1556373A1 (en) * 2002-10-18 2005-07-27 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
WO2004047827A1 (en) * 2002-11-25 2004-06-10 Pfizer Products Inc. Method for promoting nail growth using thyromimetic compounds
DE602004022153D1 (de) * 2003-05-14 2009-09-03 High Point Pharmaceuticals Llc Verbindungen zur behandlung von obesitas
NO319624B1 (no) 2003-09-15 2005-09-05 Trouw Internat Bv Fiskefôr for laksefisk i ferskvann og anvendelse av slikt fôr.
ES2544477T3 (es) * 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
JP2007512359A (ja) 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
EP1689707A1 (en) * 2003-11-25 2006-08-16 Novo Nordisk A/S Novel compounds for the treatment of obesity
WO2005077903A2 (en) * 2004-02-09 2005-08-25 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted tetrahydroisoquinoline analogues
EP1863804A1 (en) * 2005-04-01 2007-12-12 Methylgene, Inc. Inhibitors of histone deacetylase
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
WO2007002036A1 (en) * 2005-06-24 2007-01-04 Thomas Lavin Tyroid hormone in burn and adipose deposites
GB0513692D0 (en) * 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
NZ565190A (en) * 2005-07-21 2010-02-26 Hoffmann La Roche Pyridazinone derivatives as thyroid hormone receptor agonists
GB0608724D0 (en) 2006-05-03 2006-06-14 Karobio Ab Novel Pharmaceutical Compositions
GB0610322D0 (en) * 2006-05-24 2006-07-05 Karobio Ab Novel pharmaceutical compositions
CA2655913A1 (en) * 2006-06-28 2008-01-03 Sanwa Kagaku Kenkyusho Co., Ltd. Novel 6-5 system bicyclic heterocyclic derivative and its pharmaceutical utility
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
RS51501B (sr) 2007-06-06 2011-04-30 Torrent Pharmaceuticals Ltd Nova jedinjenja
CN101903338A (zh) 2007-12-19 2010-12-01 安姆根有限公司 用作炎症调节剂的苯基乙酸衍生物
EP2346814A2 (en) * 2008-10-27 2011-07-27 Cadila Healthcare Limited Thyroid receptor ligands
CN110200955A (zh) * 2010-10-30 2019-09-06 金戴克斯治疗学有限责任公司 四氢异-α酸衍生物、组合物及方法
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9594070B2 (en) * 2013-11-05 2017-03-14 Spectrum Tracer Services, Llc Method using halogenated benzoic acid esters and aldehydes for hydraulic fracturing and for tracing petroleum production
CN104193699B (zh) * 2014-08-14 2016-05-25 嘉兴特科罗生物科技有限公司 一种小分子化合物及其合成方法和应用
US10017684B2 (en) * 2016-04-20 2018-07-10 Spectrum Tracer Services, Llc Method and compositions for hydraulic fracturing and for tracing formation water
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
BR112019025659A2 (pt) 2017-06-05 2020-08-25 Viking Therapeutics, Inc. composições para o tratamento de fibrose
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
EP3890747A4 (en) 2018-12-05 2022-08-03 Viking Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION
CA3185296A1 (en) * 2020-07-10 2022-01-13 David Craig Mcgowan Modulators of thr-? and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069343A (en) 1973-03-23 1978-01-17 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4554290A (en) 1983-06-17 1985-11-19 Ciba-Geigy Corporation Oxamic acid derivatives
US5061798A (en) 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5232947A (en) 1988-07-04 1993-08-03 Meiji Seika Kaisha, Ltd. Oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
US5284971A (en) 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
EP0580550B1 (en) * 1992-07-21 1997-10-22 Novartis AG Oxamic acid derivatives as hypocholesteremic agents
GB9816935D0 (en) * 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
OA11839A (en) * 1999-03-01 2005-08-23 Pfizer Prod Inc Oxamic acids and derivatives as thyroid receptor ligands.
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .

Also Published As

Publication number Publication date
PT1157001E (pt) 2004-10-29
PL364802A1 (en) 2004-12-13
AU2457500A (en) 2000-09-21
CZ20013117A3 (cs) 2002-06-12
BG105954A (en) 2002-06-28
IL144765A0 (en) 2002-06-30
TR200102561T2 (tr) 2002-02-21
KR20010103786A (ko) 2001-11-23
GT200000025A (es) 2001-08-22
HK1044532A1 (zh) 2002-10-25
JP3699355B2 (ja) 2005-09-28
OA11839A (en) 2005-08-23
EA200100841A1 (ru) 2002-02-28
JP2005162759A (ja) 2005-06-23
BR0008701A (pt) 2001-12-26
DE60012700T2 (de) 2005-07-28
ES2223454T3 (es) 2005-03-01
ID29889A (id) 2001-10-18
CN1345303A (zh) 2002-04-17
UY26043A1 (es) 2000-09-29
IS6054A (is) 2001-08-17
DZ3020A1 (fr) 2004-03-20
YU63301A (sh) 2004-09-03
NO20014217D0 (no) 2001-08-31
CA2363145C (en) 2006-02-14
US6545018B2 (en) 2003-04-08
SK12102001A3 (sk) 2002-10-08
NZ513449A (en) 2004-02-27
US20020049226A1 (en) 2002-04-25
EP1157001A1 (en) 2001-11-28
AP2001002259A0 (en) 2001-09-30
CO5150228A1 (es) 2002-04-29
CA2363145A1 (en) 2000-09-08
ZA200106730B (en) 2002-08-05
HUP0200248A3 (en) 2002-11-28
PA8491501A1 (es) 2001-04-30
TNSN00036A1 (fr) 2005-11-10
ATE272609T1 (de) 2004-08-15
US6326398B1 (en) 2001-12-04
HN2000000029A (es) 2001-02-02
JP2002538133A (ja) 2002-11-12
HRP20010633A2 (en) 2002-10-31
EE200100464A (et) 2002-12-16
CR6451A (es) 2004-03-24
US20030114521A1 (en) 2003-06-19
GT200000025AA (es) 2001-08-22
MA26723A1 (fr) 2004-12-20
AR033791A1 (es) 2004-01-07
NO20014217L (no) 2001-10-11
EA004229B1 (ru) 2004-02-26
WO2000051971A1 (en) 2000-09-08
EP1157001B1 (en) 2004-08-04
AU772282B2 (en) 2004-04-22
CN1515548A (zh) 2004-07-28
DE60012700D1 (de) 2004-09-09
HUP0200248A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
PE20001483A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20081448A1 (es) Inhibidores de transcriptasa inversa no nucleosidicos
PE20001600A1 (es) Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20081316A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
PE20040290A1 (es) Derivados de piperidinas- benzodiazepinas como antagonistas del cgrp
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20020593A1 (es) Activadores de glucocinasa del tipo isoindolin-2-ona
PE20011114A1 (es) Decahidro-isoquinolinas
PA8581401A1 (es) Compuestos de imedazopiridina como agonistas del receptor 5-ht4
PE20081378A1 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
PE20040672A1 (es) Derivados de fenil o heteroaril amino alcano
PE20040599A1 (es) Amidas sustituidas como moduladores del receptor cannabinoide-1 (cb1)
EA200970326A1 (ru) Алкильные производные в качестве метаботропных рецепторов глутамата
PE20021011A1 (es) Derivados quinazolinicos como inhibidores de la rho-quinasa
PE20030497A1 (es) Combinaciones de un inhibidor de pde 5 y otros agentes activos
PE20040987A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
AR030913A1 (es) Un compuesto derivado de indolina, su uso, un procedimiento para prepararlo, una composicion farmaceutica que lo comprende y un procedimiento para preparar dicha composicion
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1
PE20001556A1 (es) Derivados de tetrahidropirano utiles como antagonistas de taquicinina
RU2005117374A (ru) Индолы, полезные для лечения заболеваний, связанных с андрогеновыми рецепторами

Legal Events

Date Code Title Description
FC Refusal